Where Biotech Innovation Drives Growth

September 2026

VanEck

VanEck Biotech ETF

BBH

Biotechnology is Redefining Healthcare

Biotechnology is driving a new era of medicine focused on precision, prevention, and disease modification. Advances in genomics, gene editing, and biologics are enabling more targeted treatments and improved patient outcomes as therapies move from research to commercialization. As of 2025, nearly 50 cell and gene therapies have received FDA approval, with forecasts projecting **more than 200 approvals by 2030**, underscoring the rapid pace of progress.


Source: fda.gov; cardinalhealth.com

Biotech Platforms Support Long-Term Value Creation

Biotechnology platforms support long-term value creation by enabling repeatable innovation across multiple therapies. Advances in genomics, gene editing, and biologics are improving R&D efficiency and accelerating the path from discovery to commercialization, helping build durable pipelines beyond individual drug launches.

Medicine 2.0 vs. 3.0 | 2.0 Will Keep You Alive, 3.0 Will Let You Live

Biotechnology is enabling a shift from reactive, disease-focused care toward personalized and proactive medicine that targets the underlying biology of disease.



Source: Attia MD, Peter. *Outlive: The Science & Art of Longevity*. Harmony, 2023.

Why BBH?

Highly Liquid Companies

Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume

Industry Leaders

Index methodology favors the largest companies in the industry

Global Scope

Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Medicine 1.0 - Reactive; trial-and-error treatments based on observation

Medicine 2.0 - Disease-focused; standardized care guided by clinical trials

Medicine 3.0 - Personalized, proactive care using diagnostics and biotech

Source: Attia MD, Peter.

VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

Fund Ticker	BBH
Commencement Date	12/20/2011
Net Expense Ratio (%)	0.35
Gross Expense Ratio (%)	0.35

Van Eck Associates Corporation (the "Adviser") will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2027. "Other Expenses" have been restated to reflect current fees.

Total Return (%) as of 09/30/2026		BBH	MVBBHTR
YTD*	NAV	29.13	29.23
	Share Price	29.22	
1 Yr	NAV	48.19	48.36
	Share Price	48.35	
3 Yr	NAV	16.87	16.96
	Share Price	16.90	
5 Yr	NAV	4.37	4.47
	Share Price	4.38	
10 Yr	NAV	8.28	8.42
	Share Price	8.30	
Since Fund Inception 12/20/2011	NAV	14.38	14.54
	Share Price	14.39	

*Returns less than one year are not annualized.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Please call 800.826.2333 or visit vaneck.com for performance current to the most recent month ended.

The "Net Asset Value" (NAV) of a Fund is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. Investors should not expect to buy or sell shares at NAV.Index returns assume reinvestment of all income and do not reflect any management fees or brokerage expenses associated with fund returns. Returns for actual fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. You cannot invest directly in an index.

MVIS® US Listed Biotech 25 Index (MVBBHTR) is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

MarketVector Indexes GmbH develops, monitors and markets the MarketVector Indexes, a focused selection pf pure-play and investable indices designed to underlie financial products. They cover several asset classes including hard assets and the internal equity markets as well as fixed income markets. MarketVector Indexes GmbH is the index business of VanEck, a U.S. based investment management firm and provider of VanEck ETFs.

MarketVector Indexes GmbH does not sponsor, endorse, sell, promote or manage any investment fund or other investment vehicle that is offered by third parties and that seeks to provide and investment return based on the performance of any index. MarketVector Indexes GmbH makes no assurance that investment products based on the index will accurately track index performance or provide positive investment returns. MarketVector Indexes GmbH is not an investment advisor, and it makes no representation regarding the advisability of investing in any such investment fund or other investment vehicle. A decision to invest in any such investment fund or other investment vehicle should not be made in reliance on any of the statements set forth in this document.

An investment in the Fund may be subject to risks which include, among others, risks related to investing in the biotechnology industry, equity securities, life sciences tools and services industry, depositary receipts, medium-capitalization companies, issuer-specific changes, market, operational, index tracking, authorized participant concentration, no guarantee of active trading market, trading issues, passive management, fund shares trading, premium/discount risk and liquidity of fund shares, non-diversified, and index-related concentration risks, all of which may adversely affect the Fund. Medium-capitalization companies may be subject to elevated risks.

Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of a Fund carefully before investing. To obtain a prospectus and summary prospectus, which contain this and other information, call 800.826.2333 or visit vaneck.com. Please read the prospectus and summary prospectus carefully before investing.

© 2026 VanEck